Skip to main content
. 2022 Jul 7;13(4):e01612-22. doi: 10.1128/mbio.01612-22

FIG 3.

FIG 3

mL (G12-scFv) decreased HBsAg in AAV/HBV mouse model. (A) AAV/HBV mice were injected with 2.5 mg/kg mL (G12-scFv) or 6.7 mg/kg G12-scFv. (B) Kinetics of HBsAg levels in 30 days posttreatment. HBsAg levels were quantified on day 1 (C), day 2 (D), day 5 (E), day 9 (F), day 12 (G), day 15 (H), day 20 (I), day 26 (J), and day 30 (K) posttreatment.